Insider Trades of DOERING RUTH SELIGMAN
Click on the column header to resort 'ascending (^) or descending (v).
Individual Insider Trades
| Company | Relation | Last Date | Tran |
OwnerType | Shares Traded | Last Price | Shares Held |
|---|---|---|---|---|---|---|---|
| BANK OF KENTUCKY FINANCIAL CORP | Director | 12/01/2011 | Disposition (Non Open Market) | indirect | 1,262 | 0 | 104,730 |
| BANK OF KENTUCKY FINANCIAL CORP | Director | 12/01/2011 | Disposition (Non Open Market) | direct | 0 | 100 | |
| BANK OF KENTUCKY FINANCIAL CORP | Director | 02/17/2012 | Disposition (Non Open Market) | indirect | 1,102 | 0 | 103,628 |
| BANK OF KENTUCKY FINANCIAL CORP | Director | 02/17/2012 | Disposition (Non Open Market) | direct | 0 | 100 | |
| BANK OF KENTUCKY FINANCIAL CORP | Director | 11/29/2012 | Disposition (Non Open Market) | indirect | 102,868 | 0 | 1,810 |
| BANK OF KENTUCKY FINANCIAL CORP | Director | 12/07/2012 | Buy | indirect | 138 | 24.63 | 1,948 |
| BANK OF KENTUCKY FINANCIAL CORP | Director | 12/10/2012 | Buy | indirect | 1,621 | 24.6 | 3,569 |
| BANK OF KENTUCKY FINANCIAL CORP | Director | 12/11/2012 | Buy | indirect | 212 | 24.62 | 3,781 |
| BANK OF KENTUCKY FINANCIAL CORP | Director | 12/12/2012 | Buy | indirect | 400 | 24.64 | 4,181 |
| BANK OF KENTUCKY FINANCIAL CORP | Director | 12/13/2012 | Buy | indirect | 129 | 24.64 | 4,310 |
| BANK OF KENTUCKY FINANCIAL CORP | Director | 01/16/2013 | Acquisition (Non Open Market) | indirect | 1,500 | 22.51 | 5,810 |
| BANK OF KENTUCKY FINANCIAL CORP | Director | 04/22/2013 | Acquisition (Non Open Market) | direct | 465 | 25.8 | 565 |
Latest News Headlines
Royalty Pharma Lowers Acceptance Threshold For Elan Offer 8:17AM ET - Dow Jones Business News
EBay Names Former Microsoft Executive Its New India Head 8:09AM ET - Dow Jones Business News
Oculus Innovative Sciences Announces Fiscal Fourth Quarter 2013 Financial Results and Conference Ca 8:08AM ET - GlobeNewswire
Blankfein: Goldman Committed to China After ICBC Sale -Bloomberg 8:04AM ET - Dow Jones Business News
Celgene: FDA Gives Priority Review to Supplemental NDA for Abraxane 8:04AM ET - Dow Jones Business News
View All